Finding value in an era of high-priced drugs

The pricing of new drugs has always been a controversial subject. New, usually single source, and ever more expensive, treatments appear every year, stoking the controversy to a fever pitch. While “expensive” used to mean hundreds of dollars annually per patient, it can now mean hundreds of thousands of dollars. With prices changing so rapidly, and new products being introduced so frequently, how can we make evidence-informed decisions about what to cover, ensure we are getting good value for money, and still make treatments accessible to patients? At the 2015 CHSPR Conference we will hear some of the top experts in the field discuss whether we’re getting what we pay for… or paying for what we get.

Neil Palmer (PDCI’s President and Principal Consultant) will be speaking at the CHSPR 2015 27th Annual Health Policy Conference. (Topic TBD)